Volume 6.41 | Oct 30

Prostate Cell News 6.41 October 30, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Dickkopf-3 Regulates Prostate Epithelial Cell Acinar Morphogenesis and Prostate Cancer Cell Invasion by Limiting TGF-β-Dependent Activation of Matrix Metalloproteases
Scientists examined the effects of Dickkopf-3 (Dkk-3) on the expression and activity of matrix metalloproteases (MMPs), which mediate the effects of transforming growth factor (TGF)-β on extracellular matrix disassembly during tissue morphogenesis and promote invasion of tumor cells. Silencing of Dkk-3 in prostate epithelial cells resulted in increased expression and enzyme activity of MMP-2 and MMP-9. [Carcinogenesis] Abstract
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
PUBLICATIONS (Ranked by impact factor of the journal)

DAB2IP Loss Confers the Resistance of Prostate Cancer to Androgen Deprivation Therapy through Activating STAT3 and Inhibiting Apoptosis
Researchers showed that DAB2IP knockdown could significantly enhance in vitro growth and colony formation of prostate cancer cells following androgen deprivation therapy as well as tumorigenicity in pre-castrated nude mice. [Cell Death Dis] Full Article

Characterization of a Novel Metastatic Prostate Cancer Cell Line of LNCaP Origin
Scientists describe the characteristics of a new LNCaP derivative, JHU-LNCaP-SM, which was generated by long term passage in normal cell culture conditions. [Prostate] Abstract

PDLIM2 Suppression Efficiently Reduces Tumor Growth and Invasiveness of Human Castration-Resistant Prostate Cancer-Like Cells
Researchers explored the role of PDLIM2 and the effect of the PDLIM2 gene suppression on oncogenic phenotypes of human castration-resistant prostate cancer-like cells. [Prostate] Abstract

Tumor-Suppressive MicroRNA-223 Inhibits Cancer Cell Migration and Invasion by Targeting ITGA3/ITGB1 Signaling in Prostate Cancer
Researchers investigated the functional roles of microRNA (miR)-223 and identified downstream oncogenic targets regulated by miR-223 in prostate cancer (PCa) cells. Functional studies of miR-223 were performed to investigate cell proliferation, migration and invasion using PC3 and PC3M PCa cell lines. [Cancer Sci] Abstract

Elevated Expression of Hepatoma Up-Regulated Protein Inhibits γ- Irradiation- Induced Apoptosis of Prostate Cancer Cells
Investigators demonstrated for the first time prostate cancer (PCa) radio-resistance as a consequence of elevated expression of hepatoma up-regulated protein (HURP). In PCa cells, HURP expression suppresses γ- irradiation- induced apoptosis. [J Cell Biochem] Abstract

Inhibition on Proteasome β1 Subunit Might Contribute to the Anti-Cancer Effects of Fangchinoline in Human Prostate Cancer Cells
In cultured prostate PC-3 cells and LnCap cells, fangchinoline could dose-dependently inhibit cell proliferation and caspase-like activity of the cellular proteasome which was mediated by proteasome β1 subunit. The inhibitive effect of fangchinoline on caspase-like activity of the proteasome was also observed in the purified human erythrocyte 20S proteasome. [PLoS One] Full Article

Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Scientists present evidence that the Wnt/β-catenin pathway might be activated in prostate cancer cells after androgen-deprivation to promote androgen-independent growth, partly through enhanced interaction of β-catenin with TCF4. [PLoS One] Full Article

Matrine Inhibits the Proliferation, Invasion and Migration of Castration-Resistant Prostate Cancer Cells through Regulation of the NF-κB Signaling Pathway
Investigators showed that matrine inhibited the proliferation, migration and invasion of both DU145 and PC-3 cells in a dose- and time-dependent manner. [Oncol Rep] Abstract

Pin1 Promotes Prostate Cancer Cell Proliferation and Migration through Activation of Wnt/β-Catenin Signaling
The authors investigated the clinical significance of Pin1 and its function in prostate cancer tumor progression. [Clin Transl Oncol] Abstract


DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
The authors conducted a Phase II trial in which patients with metastatic, castration-resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. [N Engl J Med] Abstract

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-Hoc Analysis of Randomized Phase III Studies
Researchers describe a post-hoc exploratory analysis of randomized Phase III studies examining post-docetaxel or chemotherapy-naïve metastatic castration-resistant prostate cancer patients receiving abiraterone acetate. [Eur Urol] Abstract

Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
Prostate Cancer Stem Cells: The Role of Androgen and Estrogen Receptors
Scientists discuss the still-debated mechanisms, both genomic and non-genomic, by which androgen and estradiol receptors (classical and novel) mediate the hormonal control of prostate cell stemness, transformation, and the continued growth of prostate cancer. [Oncotarget] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Transition Therapeutics Announces Agreement for Phase II Study of TT701 Drug Candidate
Transition Therapeutics Inc. announced that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital. [Transition Therapeutics Inc.] Press Release

$20 Million Commonwealth Foundation for Cancer Research Gift to Expand Collaborative Cancer Research
The Commonwealth Foundation for Cancer Research has pledged $20 million to the Bridge Project, a collaborative research program of the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology and the Dana-Farber/Harvard Cancer Center, to accelerate the translation of interdisciplinary cancer solutions toward the clinic. [Massachusetts Institute of Technology] Press Release

From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 28th Lorne Cancer Conference
February 11-13, 2016
Lorne, Australia

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Position – Androgen Response in Prostate Cancer (University of Victoria)

NEW Computational Biologist – Prostate Cancer (Cancer Research UK Manchester Institute)

Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us